Differentiating between effects of streptozotocinper seand subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model

2004 ◽  
Vol 20 (6) ◽  
pp. 452-459 ◽  
Author(s):  
Fredrik Palm ◽  
Henrik Ortsäter ◽  
Peter Hansell ◽  
Per Liss ◽  
Per-Ola Carlsson
Keyword(s):  
Renal Function ◽  
Rat Model ◽  
Diabetic Rat ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

Beneficial effect of PEDF-transfected ADSCs on erectile dysfunction in a streptozotocin-diabetic rat model

2016 ◽  
Vol 366 (3) ◽  
pp. 623-637 ◽  
Author(s):  
Jun Lu ◽  
Zhixiang Xin ◽  
Qi Zhang ◽  
Di Cui ◽  
Yinglong Xiao ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Beneficial Effect ◽  
Rat Model ◽  
Diabetic Rat ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

scholarly journals Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model

2010 ◽  
Vol 79 (7) ◽  
pp. 1007-1014 ◽  
Author(s):  
Hanna Shevalye ◽  
Roman Stavniichuk ◽  
Weizheng Xu ◽  
Jie Zhang ◽  
Sergey Lupachyk ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Rat Model ◽  
Parp Inhibition ◽  
Diabetic Rat ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications

2019 ◽  
Vol 16 (1) ◽  
pp. 26-39 ◽  
Author(s):  
Mirza Anwar Baig ◽  
Shital Sharad Panchal
Keyword(s):  
Diabetes Mellitus ◽  
Animal Model ◽  
Animal Models ◽  
Rat Model ◽  
Diabetic Complications ◽  
Research Work ◽  
Diabetic Rat ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

Background: Diabetic complications are the major contributor in the mortality of diabetic patients despite controlling blood glucose level. In the journey of new drug discovery, animal models have to play a major role. A large number of chemical-induced and genetically modified animal models have been investigated to induce diabetic complications but none of them was found to be mimicking the pathophysiology of the human. Therefore, the search and identification of the appropriate animal model become essential. Objective: In the present review, we have made an attempt to understand the pathophysiology of diabetic complication in the neonatal streptozotocin-diabetic rat model and tried to identify the targets for therapeutic agents. The review will help the researchers to explore the animal model to induce diabetic complications, to identify targets and further to find lead molecules for treatment or prevention of diabetic complications. Methods: We have compiled the available research work from 1974 by using prominent databases, organized the available information and analyzed the data to improve the understanding of the pathophysiology of streptozotocin-induced diabetic complications in neonates of rats. Results: The neonatal streptozotocin-diabetic rat model is frequently used and well-established animal model for type 2 diabetes mellitus. We have found that this model has been used to study the pathogenesis of various micro and macrovascular diabetic complications and also investigated for its effects on the liver, thymus gland, and brain. The underlying pathophysiology for complications had a resemblance to the human. Conclusion: The neonatal streptozotocin-diabetic rat model may demonstrate symptomatic diabetic complications due to persistent hyperglycemia at the age of approximately 18-24 weeks. Critical interpretations of available research work showed that the researcher can explore split dose STZ (90- 100mg/kg b.w) model to induce Type 2 DM in neonates of rats at 2nd or 3rd postnatal day.

scholarly journals Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

Diabetologia ◽  
2004 ◽  
Vol 47 (4) ◽  
pp. 710-717 ◽  
Author(s):  
O. I. Abatan ◽  
T. Charniauskaya ◽  
M. J. Stevens ◽  
I. G. Obrosova ◽  
P. Pacher ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Rat Model ◽  
Diabetic Rat ◽  
Polymerase Inhibitor ◽  
Orally Active ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

Camel milk ameliorates the coagulopathy in streptozotocin diabetic rat model

2014 ◽  
Vol 68 (1) ◽  
pp. 79-87 ◽  
Author(s):  
Aida A Korish ◽  
Abdel Galil M Abdel Gader ◽  
Abdulqader A Alhaider
Keyword(s):  
Rat Model ◽  
Camel Milk ◽  
Diabetic Rat ◽  
Diabetic Rat Model ◽  
Streptozotocin Diabetic Rat

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

2019 ◽  
Vol 19 (5) ◽  
pp. 622-631 ◽  
Author(s):  
Ya Liu ◽  
Jian Kang ◽  
Hong Gao ◽  
Xiyu Zhang ◽  
Jun Chao ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Signaling Pathway ◽  
Rat Model ◽  
Mtor Signaling ◽  
Diabetic Rat ◽  
Gene Microarray ◽  
Mtor Signaling Pathway ◽  
Glucose Fluctuation ◽  
Blood Glucose Fluctuation ◽  
Diabetic Rat Model

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.

scholarly journals Jinmaitong decreases sciatic nerve DNA oxidative damage and apoptosis in a streptozotocin-induced diabetic rat model

2015 ◽  
Vol 10 (2) ◽  
pp. 778-786 ◽  
Author(s):  
DE-HAI YIN ◽  
XIAO-CHUN LIANG ◽  
LI ZHAO ◽  
HONG ZHANG ◽  
QING SUN ◽  
...  
Keyword(s):  
Sciatic Nerve ◽  
Oxidative Damage ◽  
Rat Model ◽  
Diabetic Rat ◽  
Dna Oxidative Damage ◽  
Diabetic Rat Model
Sign in / Sign up

Export Citation Format

Share Document